Skip to content

Assessment of the Effect of Spa Treatment on the Functional Severity of Arthrosis

Evolution of Clinical State of Patients With Rheumatic Disease on Lower Limbs or Rachis, 6 Months After Spa Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03336099
Acronym
VALS
Enrollment
120
Registered
2017-11-08
Start date
2016-03-29
Completion date
2017-06-13
Last updated
2017-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee, Pain

Brief summary

Assessment of the effect of spa treatment on the functional severity of arthrosis. Official title: Evolution of clinical state of patients with rheumatic disease on lower limbs or rachis, 6 months after spa treatment. Primary outcome measure: * Measuring the effect of spa treatment on functional severity of arthrosis * Proportion of patients with a WOMAC score augmented by 9 or more, 6 months after enrollment (minimal clinically important difference) Secondary outcome measures * Quantitative evaluation of pain * Comparison of mean Visual Analogue Scale (VAS) pain scale between enrollment and 6 months after * Quantitative evaluation of WOMAC * Comparison of mean WOMAC between enrollment and 6 months after * Impact of spa treatment on the patient's metabolism * Height and Weight (BMI calculation) * Blood pressure * Heart rate * Quality of life * 36-Item Short Form (SF36) at enrollment, 3 months and 6 months * EuroQol 5 Dimensions (EQ5D) questionnaire at enrollment, 3 months and 6 months * Opinion of doctor and patient * Semi-quantitative scale collected at enrollment, 3 months and 6 months * Treatment follow-up * Self-evaluation of pain * Self-evaluation of pain with VAS pain scale every 6 week

Detailed description

Arthrosis and rheumatic diseases on the whole consist in a huge and frequent public health problem, with consequences notably including the well-known pain phenomena. Spa treatments are part of the mainstream therapeutic arsenal of non-medical treatments proposed to this kind of patients. A recent French study estimated the direct cost of arthrosis in France to 1.6 billion euros in 2002. Half of it was attributable to hospital expenses (800 million euros). Arthrosis required 13 million consultations and drug expenses amounting to 570 million euros. These expenses were increased by 156% compared to 1993 due to the raise of the number of treated patients (+54%) and the cost for each patient (+2.5% per year). This study concerned patients with arthrosis on the lower limbs, with an significant portion of these expenses attributable to the disease. Different thermal clinical trials of good quality have led to the recognition of spa in the treatment of chronic low back pain. Several controlled and randomized prospective trials already evaluated the effect of spa treatment for the other main indications claimed by crenotherapy in rheumatology : chronic low back pain, coxarthrosis, hand arthrosis, fibromyalgia, rheumatoid polyarthritis, psoriatic arthritis, chronic cervicalgia. The THERMARTHROSE study by Forestier has demonstrated the efficacy of spa treatment as a rheumatologic indication for gonarthrosis on WOMAC and VAS pain scale. Following the model of this study, the sponsor chose to use the WOMAC as the primary endpoint for the VALS study. It has been developed by Bellamy in 1988, and it is a functional index aimed on the locomotor system. Nowadays, the WOMAC is more used than the Lequesne index because it has better internal consistency reliability. However, complementary validation efforts were necessary to calculate the minimal clinically important difference whereas the pertinence of the Lequesne index is immediately perceptible, being purely qualitative. With studies in thermal environment, spa treatment is a composite entity including the effect of water itself, but also kinesiotherapy, rest, education… The spa of Vals-les-Bains wishes to obtain a new therapeutic orientation: the rheumatologic orientation. According to the recommendations of the Academy of Medicine, a prolonged observation of a cohort with repeated measures is required for any spa wishing to acquire the accreditation for a new orientation. Toward this goal, the sponsor wish to undertake a prospective study with repeated measures in order to analyze the evolution at 6 month of the clinical state of patients with a rheumatologic disease on the lower limbs or the rachis and taken over for spa treatment at Vals-les-Bains. Since rheumatologic treatments at Vals-les-Bains are not covered by the health insurance, they will not be billed to the patients

Interventions

* Bath with immersion shower * Overall shower, penetrating shower * Multiple local application cataplasm * Single local application cataplasm * Inhalation or collective steam bath * Individual physiotherapy technique

Sponsors

Floralis
CollaboratorINDUSTRY
Le Syndicat Intercommunal pour le Thermalisme et l'Environnement
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with arthrosis or other rheumatic disease, located on the lower limbs or the rachis * Rheumatic indication for spa treatment * Diminution of mobility * Affiliation to the French social security system or equivalent * Available for a 6-months follow-up and an 18-days spa treatment

Exclusion criteria

* Pregnancy, parturient or breast feeding * Psychiatric illness or social situation that would preclude study compliance * Contraindication to spa treatment * Predictable intolerance to thermal treatment

Design outcomes

Primary

MeasureTime frameDescription
Measuring the effect of spa treatment on functional severity of arthrosis6 monthsProportion of patients with a WOMAC score augmented by 9 or more, at 6 months compared to baseline (minimal clinically important difference)

Secondary

MeasureTime frameDescription
Quality of lifeat baseline, 3 and 6 monthsSF36 questionnaire at baseline, 3 and 6 months
Opinion of doctor and patientat baseline, 3 and 6 monthsSemi-quantitative scale collected at baseline, 3 and 6 months
Quantitative evaluation of painat baseline, 3 and 6 monthsComparison of mean VAS pain scale between baseline, 3 and 6 months
Quantitative evaluation of WOMACat baseline, 3 and 6 monthsComparison of mean WOMAC between baseline, 3 months and 6 months
Patient's BMIat baseline, 3 and 6 monthsweight and height will be combined to report BMI in kg/m2
Number of treatments prescribedat baseline, 3 and 6 monthsType of treatments prescribed at baseline, 3 and 6 months will be collected
Changes in treatments prescribedat baseline, 3 and 6 monthschanges in treatments prescribed at baseline, 3 and 6 months will be collected
Treatments durationat baseline, 3 and 6 monthsDuration of treatments prescribed at baseline, 3 and 6 months will be collected
Self-evaluation of painat baseline, 1.5, 3, 4.5 and 6 monthsSelf-evaluation of pain with VAS pain scale at baseline, 1.5, 3, 4.5 and 6 months
patient examinationat baseline, 3 and 6 monthsheart rate

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026